Strategies to Prevent Invasive Candidal Infection in Extremely Preterm Infants

Clinics in Perinatology

Volumn 37, Issue 3, 2010, Pages 611-628

  Kaufman, David A ^a   Manzoni, Paolo ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Sant'Anna Hospital   (Italy)

Author keywords

Antifungal prophylaxis; Fluconazole; Invasive candidal infection; Preterm infants

Indexed keywords

FLUCONAZOLE; LACTOFERRIN; NYSTATIN; PLACEBO; PROBIOTIC AGENT;

ANTIFUNGAL SUSCEPTIBILITY; BREAST FEEDING; CATHETER INFECTION; CENTRAL VENOUS CATHETERIZATION; CHOLESTASIS; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERADICATION THERAPY; EXTREMELY LOW BIRTH WEIGHT; FUNGUS CULTURE; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; INFANT NUTRITION; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INVASIVE CANDIDIASIS; LENGTH OF STAY; MATERNAL DISEASE; NECROTIZING ENTEROCOLITIS; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; PREMATURE LABOR; PREMATURITY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VAGINA CANDIDIASIS;

ANTIFUNGAL AGENTS; CANDIDIASIS; DISEASE PROGRESSION; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 77956158918     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.06.003     Document Type: Review

References (63)

1. Johnsson H., Ewald U. The rate of candidaemia in preterm infants born at a gestational age of 23-28 weeks is inversely correlated to gestational age. Acta Paediatr 2004, 93:954-958.
2. Zaoutis T.E., Heydon K., Localio R., et al. Outcomes attributable to neonatal candidiasis. Clin Infect Dis 2007, 44:1187-1193.
3. Fridkin S.K., Kaufman D., Edwards J.R., et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006, 117:1680-1687.
4. Stoll B.J., Hansen N.I., Adams-Chapman I., et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004, 292:2357-2365.
5. Benjamin D.K., Stoll B.J., Fanaroff A.A., et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117:84-92.
6. Smith P.B., Morgan J., Benjamin J.D., et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J 2007, 26:197-200.
7. Kaufman D., Boyle R., Hazen K.C., et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345:1660-1666.
8. Manzoni P., Stolfi I., Pugni L., et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356:2483-2495.
9. Manzoni P., Farina D., Galletto P., et al. Type and number of sites colonized by fungi and risk of progression to invasive fungal infection in preterm neonates in neonatal intensive care unit. J Perinat Med 2007, 35:220-226.
10. Manzoni P., Farina D., Leonessa M., et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006, 118:2359-2364.
11. Kaufman D., Boyle R., Hazen K.C., et al. Twice weekly fluconazole prophylaxis for prevention of invasive candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005, 147:172-179.
12. Kicklighter S.D., Springer S.C., Cox T., et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001, 107:293-298.
13. Aghai Z.H., Mudduluru M., Nakhla T.A., et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006, 26:550-555.
14. Manzoni P., Arisio R., Mostert M., et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics 2006, 117:e22-e32.
15. Bertini G., Perugi S., Dani C., et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005, 147:162-165.
16. Uko S., Soghier L.M., Vega M., et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006, 117:1243-1252.
17. Healy C.M., Baker C.J., Zaccaria E., et al. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005, 147:166-171.
18. Healy C.M., Campbell J.R., Zaccaria E., et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008, 121:703-710.
19. Weitkamp J.H., Ozdas A., Lafleur B., et al. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 2008.
20. Aziz M., Patel A.L., Losavio J., et al. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr Infect Dis J 2010, 29:352-356.
21. Dutta S., Murki S., Varma S., et al. Effects of cessation of a policy of neonatal fluconazole prophylaxis on fungal resurgence. Indian Pediatr 2005, 42:1226-1230.
22. McCrossan B.A., McHenry E., O'Neill F., et al. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed 2007, 92:F454-F458.
23. Violaris K., Carbone T., Bateman D., et al. Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants. Am J Perinatol 2010, 27:73-78.
24. Sims M.E., Yoo Y., You H., et al. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988, 5:33-36.
25. Ozturk M.A., Gunes T., Koklu E., et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006, 49:484-492.
26. Ganesan K., Harigopal S., Neal T., et al. Prophylactic oral nystatin for preterm babies under 33 weeks gestation decreases fungal colonisation and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed 2009, 94:F275-F278.
27. Howell A.J., Isaacs D., Halliday R. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009, 94:F429-F433. adc.
28. Parikh T.B., Nanavati R.N., Patankar C.V., et al. Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr 2007, 44:830-837.
29. Kaufman D.A. Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU?. Curr Opin Pediatr 2008, 20:332-340.
30. Manzoni P., Leonessa M., Galletto P., et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008, 27:731-737.
31. Kaufman DA, Boyle R, Grossman LB, et al. Fluconazole prophylaxis dosing and the resistance patterns in preterm infants over a 11-year period [abstract]. Pediatric Academic Society Annual Meeting. Vancouver (Canada), May 1, 2010. E-PAS20101370.7.
32. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
33. Sarvikivi E., Lyytikainen O., Soll D.R., et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005, 43:2729-2735.
34. Kaufman D. Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants. Pediatrics 2008, 122:1158-1159.
35. Jew R.K., Owen D., Kaufman D., et al. Osmolality of commonly used medications and formulas in the Neonatal Intensive Care Unit. Nutr Clin Pract 1997, 12:158-163.
36. Ernst J.A., Williams J.M., Glick M.R., et al. Osmolality of substances used in the intensive care nursery. Pediatrics 1983, 72:347-352.
37. Mutz A.E., Obladen M.W. Hyperosmolar oral medication and necrotizing enterocolitis. Pediatrics 1985, 75:371-372.
38. Makhoul I.R., Kassis I., Smolkin T., et al. Review of 49 neonates with acquired fungal sepsis: further characterization. Pediatrics 2001, 107:61-66.
39. Procianoy R.S., Eneas M.V., Silveira R.C. Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur J Pediatr 2006, 165:422-423.
40. Waggoner-Fountain L.A., Walker M.W., Hollis R.J., et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis 1996, 22:803-808.
41. Freydiere A.M., Piens M.A., Andre J.M., et al. Successful treatment of Candida glabrata peritonitis with fluconazole plus flucytosine in a premature infant following in vitro fertilization. Eur J Clin Microbiol Infect Dis 2005, 24:704-705.
42. Baley J.E., Kliegman R.M., Boxerbaum B., et al. Fungal colonization in the very low birth weight infant. Pediatrics 1986, 78:225-232.
43. Bliss J.M., Basavegowda K.P., Watson W.J., et al. Vertical and horizontal transmission of Candida albicans in very low birth weight infants using DNA fingerprinting techniques. Pediatr Infect Dis J 2008, 27:231-235.
44. Kaufman D.A. Neonatal candidiasis: clinical manifestations, management, and prevention strategies. J Pediatr 2010, 156:s53-s67.
45. Cotten C.M., McDonald S., Stoll B., et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006, 118:717-722.
46. Benjamin D.K., DeLong E.R., Steinbach W.J., et al. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 2003, 112:543-547.
47. Stoll B.J., Temprosa M., Tyson J.E., et al. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics 1999, 104:e63.
48. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004, 114:1649-1657.
49. Patel S.J., Oshodi A., Prasad P., et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 step campaign to prevent antimicrobial resistance. Pediatr Infect Dis J 2009, 28:1047-1051.
50. Chapman R.L., Faix R.G. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 2000, 19:822-827.
51. Uauy R.D., Fanaroff A.A., Korones S.B., et al. Necrotizing enterocolitis in very low birth weight infants: biodemographic and clinical correlates. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1991, 119:630-638.
52. Berseth C.L., Bisquera J.A., Paje V.U. Prolonging small feeding volumes early in life decreases the incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2003, 111:529-534.
53. Aly H., Herson V., Duncan A., et al. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics 2005, 115:1513-1518.
54. Curry S., Honeycutt M., Goins G., et al. Catheter-associated bloodstream infections in the NICU: getting to zero. Neonatal Netw 2009, 28:151-155.
55. Schulman J., Wirtschafter D.D., Kurtin P. Neonatal intensive care unit collaboration to decrease hospital-acquired bloodstream infections: from comparative performance reports to improvement networks. Pediatr Clin North Am 2009, 56:865-892.
56. Schulman J., Stricof R.L., Stevens T.P., et al. Development of a statewide collaborative to decrease NICU central line-associated bloodstream infections. J Perinatol 2009, 29:591-599.
57. Powers R.J., Wirtschafter D.W. Decreasing central line associated bloodstream infection in neonatal intensive care. Clin Perinatol 2010, 37:247-272.
58. Wirtschafter D.D., Pettit J., Kurtin P., et al. A statewide quality improvement collaborative to reduce neonatal central line-associated blood stream infections. J Perinatol 2010, 30:170-181.
59. Manzoni P., Rinaldi M., Cattani S., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009, 302:1421-1428.
60. Benjamin DK, Stoll BJ, Goldberg R, et al. Neonatal candidiasis: epidemiology, clinical judgment, and outcomes [abstract]. Pediatric Academic Societies Annual Meeting. Honolulu (HI), May 2008. E-PAS 2008:633235.2.2008.
61. Candidiasis. Red book: 2009 report of the committee on infectious diseases 2009, 245-249. American Academy of Pediatrics, Elk Grove Villiage (IL). L. Pickering, D.W. Kimberlin, C.J. Baker (Eds.).
62. The periodic health examination. Canadian Task Force on the periodic health examination. Can Med Assoc J 1979, 121:1193-1254.
63. West S., King V., Carey T.S., et al. Systems to rate the strength of scientific evidence. Evid Rep Technol Assess (Summ) 2002, 1-11.